Structure Therapeutics Inc. (GPCR)
US — Healthcare Sector
Automate Your Wheel Strategy on GPCR
With Tiblio's Option Bot, you can configure your own wheel strategy including GPCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GPCR
- Rev/Share 0.0
- Book/Share 1.4395
- PB 5.0388
- Debt/Equity 0.0092
- CurrentRatio 23.2856
- ROIC -0.2198
- MktCap 417332603.0
- FreeCF/Share -0.2378
- PFCF -3.0635
- PE -28.9918
- Debt/Assets 0.0088
- DivYield 0
- ROE -0.1635
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GPCR | Citigroup | -- | Buy | -- | $60 | May 2, 2025 |
| Initiation | GPCR | William Blair | -- | Outperform | -- | -- | Feb. 28, 2025 |
| Initiation | GPCR | Stifel | -- | Buy | -- | $50 | Jan. 8, 2025 |
| Initiation | GPCR | H.C. Wainwright | -- | Buy | -- | $80 | Dec. 4, 2024 |
| Initiation | GPCR | Morgan Stanley | -- | Overweight | -- | $118 | Sept. 23, 2024 |
News
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR,
LLY,
NVO,
VKTX
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Read More
Why Structure Therapeutics Stock Was Stumbling This Week
GPCR
Published: February 14, 2025 by: The Motley Fool
Sentiment: Negative
Published: February 14, 2025 by: The Motley Fool
Sentiment: Negative
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.
Read More
About Structure Therapeutics Inc. (GPCR)
- IPO Date 2023-02-03
- Website https://structuretx.com
- Industry Biotechnology
- CEO Dr. Raymond C. Stevens Ph.D.
- Employees 163
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.